GlobalData on MSN7d
OSE’s UC therapy prompts 16% clinical remission after ten weeks
Phase II CoTikiS study of lusvertikimab has met primary and secondary endpoints, showing high rates of clinical and ...
Hosted on MSN8d
Johnson & Johnson’s TREMFYA® Shows Promising Results in Ulcerative Colitis Patients
Johnson & Johnson (NYSE: JNJ) has announced positive results from the Phase 3 ASTRO study evaluating TREMFYA® (guselkumab) ...
BBC14d
Closure orders issued after suspected drugs misuse
Two houses have been issued closure orders due to ongoing nuisance behaviour, including suspected drug misuse, antisocial behaviour, violence, and general disorder. The orders were granted for the ...
Nature16d
Current management of severe ulcerative colitis
The timing of surgery remains a cardinal decision in the management of severe ulcerative colitis; increased morbidity resulting from prolonged ineffective medical treatment and, therefore ...
BioSpace24d
Equillium’s Itolizumab Goes Toe-to-Toe With Humira in Ulcerative Colitis
California biotech Equillium on Thursday unveiled topline Phase II data for its investigational anti-inflammatory therapy itolizumab in moderate to severe ulcerative colitis, touting remission rates ...
scimex.org28d
AI tool predicts ulcerative colitis treatment success in emergency care
A 28-year study on the serious inflammatory bowel disease, acute severe ulcerative colitis (UC) has resulted in an innovative artificial intelligence tool called the Risk of Rescue (ROR) score. This ...